These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394 [TBL] [Abstract][Full Text] [Related]
23. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Walker A; Watson C; Alexopoulos ST; Deniz B; Arnold R; Bates D Curr Med Res Opin; 2014 Apr; 30(4):629-35. PubMed ID: 24289170 [TBL] [Abstract][Full Text] [Related]
24. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence. Bacchetta F; Mathias A; Schluep M; Du Pasquier R Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319 [TBL] [Abstract][Full Text] [Related]
25. Gadolinium enhancement in brain magnetic resonance imaging in progressive multifocal leukoencephalopathy after natalizumab monotherapy: is it really atypical? Arnaud FX; Hissene A; Métivier D; Dutasta F; Berets O; N'guema B; A'teriitéhau C; Baccialone J; Potet J J Neuroradiol; 2012 Oct; 39(4):267-70. PubMed ID: 22341620 [TBL] [Abstract][Full Text] [Related]
26. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217 [TBL] [Abstract][Full Text] [Related]
27. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964 [TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444 [TBL] [Abstract][Full Text] [Related]
30. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. D'Amico E; Zanghì A; Leone C; Tumani H; Patti F Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299 [TBL] [Abstract][Full Text] [Related]
31. Natalizumab-induced PML: can the beast be tamed? Hohlfeld R J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1065. PubMed ID: 23475818 [No Abstract] [Full Text] [Related]
32. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. Hoepner R; Kolb EM; Dahlhaus S; Hellwig K; Adams O; Kleiter I; Salmen A; Schneider R; Lukas C; Chan A; Berger JR; Gold R Mult Scler; 2017 May; 23(6):830-835. PubMed ID: 27600113 [TBL] [Abstract][Full Text] [Related]